Free Trial

Enlivex Therapeutics (ENLV) Competitors

Enlivex Therapeutics logo
$1.23 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 -0.03 (-2.36%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENLV vs. TARA, ATOS, HURA, PROC, CCCC, ANIX, MIST, MCRB, HLVX, and JSPR

Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Protara Therapeutics (TARA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), Seres Therapeutics (MCRB), HilleVax (HLVX), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry.

Enlivex Therapeutics vs. Its Competitors

Protara Therapeutics (NASDAQ:TARA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A-$44.60M-$1.72-1.83
Enlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.86

Protara Therapeutics presently has a consensus target price of $20.50, indicating a potential upside of 550.79%. Enlivex Therapeutics has a consensus target price of $10.00, indicating a potential upside of 713.01%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Protara Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Enlivex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

Protara Therapeutics' return on equity of -36.37% beat Enlivex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protara TherapeuticsN/A -36.37% -33.29%
Enlivex Therapeutics N/A -57.67%-50.52%

In the previous week, Protara Therapeutics and Protara Therapeutics both had 1 articles in the media. Protara Therapeutics' average media sentiment score of 1.87 equaled Enlivex Therapeutics'average media sentiment score.

Company Overall Sentiment
Protara Therapeutics Very Positive
Enlivex Therapeutics Very Positive

Protara Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 8.4% of Protara Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Protara Therapeutics beats Enlivex Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENLV vs. The Competition

MetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$29.09M$2.42B$5.52B$9.32B
Dividend YieldN/A1.79%4.25%4.05%
P/E Ratio-1.869.1828.1519.68
Price / SalesN/A737.05438.33100.29
Price / CashN/A160.6835.5357.53
Price / Book1.234.698.235.67
Net Income-$15.01M$30.99M$3.23B$257.51M
7 Day Performance-5.38%0.60%-0.01%0.52%
1 Month Performance19.42%7.93%5.61%8.84%
1 Year Performance-12.77%-5.48%26.52%14.18%

Enlivex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENLV
Enlivex Therapeutics
2.8386 of 5 stars
$1.23
flat
$10.00
+713.0%
-12.8%$29.09MN/A-1.8670Positive News
TARA
Protara Therapeutics
2.0692 of 5 stars
$2.80
-3.1%
$20.50
+632.1%
+28.2%$111.50MN/A-1.6330Positive News
ATOS
Atossa Genetics
3.1467 of 5 stars
$0.85
-0.4%
$6.17
+629.1%
-34.7%$109.68MN/A-4.038Positive News
HURA
TuHURA Biosciences
1.3698 of 5 stars
$2.40
-3.2%
$12.67
+427.8%
N/A$108.33MN/A0.00N/A
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-62.7%$107.18M$409.92M0.004,900Gap Down
High Trading Volume
CCCC
C4 Therapeutics
2.9934 of 5 stars
$1.52
+2.7%
$12.00
+689.5%
-67.5%$105.09M$35.58M-1.03150
ANIX
Anixa Biosciences
2.9076 of 5 stars
$3.21
-0.6%
$9.00
+180.4%
-0.6%$104.04M$210K-8.455News Coverage
MIST
Milestone Pharmaceuticals
2.7301 of 5 stars
$2.17
+11.9%
$7.00
+222.6%
-6.6%$103.72M$1M-2.7830Analyst Revision
High Trading Volume
MCRB
Seres Therapeutics
3.4484 of 5 stars
$10.85
-8.6%
$73.67
+579.0%
-38.4%$103.65M$126.32M-2.36330Positive News
Gap Down
HLVX
HilleVax
2.0763 of 5 stars
$2.05
-0.5%
$3.00
+46.3%
+21.7%$103.29MN/A-0.9520Positive News
JSPR
Jasper Therapeutics
3.6761 of 5 stars
$3.04
-55.1%
$48.00
+1,478.9%
-83.4%$101.70MN/A-0.5820Analyst Revision
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ENLV) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners